A Phase 2 Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 7
- 主要终点
- Response rate
研究概览
简要总结
The purpose of this phase II study is to determine the safety, tolerability, and activity of XL647 in previously untreated subjects with non-small cell lung cancer (NSCLC). XL647 is a small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), ErbB2, and EphB4. Sensitivity to EGFR inhibitors has been linked to specific EGFR mutations and associated with certain clinical characteristics in patients with NSCLC (eg, female, minimal and remote smoking history, and adenocarcinoma histology).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has NSCLC with a histologically confirmed diagnosis of adenocarcinoma with measurable disease (stage IIIB, with malignant pleural effusion, and stage IV) and either has a demonstrated activating mutation of the EGF receptor in tumor tissue or meets one of three criteria: asian, female, and minimal or no smoking history.
- •Measurable disease defined according to RECIST
- •ECOG performance status of 0 or 1
- •Normal organ and marrow function
- •No other malignancies within 5 years, except for non-melanoma skin cancer
排除标准
- •Radiation to ≥25% of bone marrow within 30 days of XL647 treatment
- •Prior systemic anticancer therapy, including cytotoxic chemotherapy, anti-VEGF, anti-VEGFR, or anti-EGFR agents or investigational drug
- •Subject has not recovered to ≤ grade 1 or to within 10% of baseline values from adverse events due to other medications administered > 30 days before study enrollment
- •Receiving anticoagulation therapy with warfarin (low-dose warfarin < 1 mg/day, heparin and low molecular weight heparins are permitted)
- •The subject meets any of the following cardiac criteria:
- •Corrected QT interval (QTc) of > 460 msec
- •Family history of congenital long QT syndrome or unexplained sudden death
- •History of sustained ventricular arrhythmias
- •Has a finding of left bundle branch block
- •Has an obligate pacemaker
- •Has important bradycardia defined as a heart rate of < 50 bpm due to sinus node dysfunction
- •Has uncontrolled hypertension
- •Has symptomatic congestive heart failure, unstable angina, or a myocardial infarction within the past 3 months
- •Has a serum potassium or serum magnesium level that falls outside the normal range
- •The subject has progressive symptomatic or hemorrhagic brain or leptomeningeal metastases
- •Uncontrolled intercurrent illness
- •Subject is pregnant or breastfeeding
- •Known HIV
研究组 & 干预措施
1
Patients received XL647 at an intermittent dosing schedule receiving drug for 5 days followed by 9 days without drug.
干预措施: XL647 (Drug)
2
Patients received drug at a daily dosing schedule
干预措施: XL647 (Drug)
结局指标
主要结局
Response rate
时间窗: Inclusion until disease progression
Safety and tolerability
时间窗: Inclusion until 30 days post last treatment
次要结局
- Pharmacokinetic and pharmacodynamic parameters(At various time points from pre-dosing until post dosing)
- Progression-free survival(Inclusion until disease progression or death)
- Duration of response(Inclusion until disease progression)
- Overall survival(Inclusion until 180-Day Follow-up post last treatment)